It is important to note that ramucirumab has been shown to improve the efficacy of EGFR TKI erlotinib in EGFR-mutant NSCLC in the first-line setting [47], in line with the hypothesis of an angiogenesis dependency in EGFR-mutant lung cancers. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.